Adamis Pharmaceuticals Corp (ADMP) SVP Sells $24,120.12 in Stock

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) SVP David J. Marguglio sold 10,579 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $2.28, for a total transaction of $24,120.12. Following the transaction, the senior vice president now owns 390,434 shares of the company’s stock, valued at approximately $890,189.52. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

NASDAQ ADMP traded down $0.02 during mid-day trading on Monday, hitting $1.98. The company’s stock had a trading volume of 182,186 shares, compared to its average volume of 406,219. Adamis Pharmaceuticals Corp has a twelve month low of $1.86 and a twelve month high of $5.10. The company has a market cap of $94.58 million, a P/E ratio of -1.98 and a beta of 1.40.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. DekaBank Deutsche Girozentrale grew its position in Adamis Pharmaceuticals by 71.4% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 1,200,000 shares of the specialty pharmaceutical company’s stock valued at $3,360,000 after purchasing an additional 500,000 shares during the period. Vanguard Group Inc grew its position in Adamis Pharmaceuticals by 27.1% in the 3rd quarter. Vanguard Group Inc now owns 1,637,513 shares of the specialty pharmaceutical company’s stock valued at $5,731,000 after purchasing an additional 348,645 shares during the period. Perceptive Advisors LLC acquired a new stake in Adamis Pharmaceuticals in the 3rd quarter valued at $481,000. Vanguard Group Inc. grew its position in Adamis Pharmaceuticals by 27.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,637,513 shares of the specialty pharmaceutical company’s stock valued at $5,731,000 after purchasing an additional 348,645 shares during the period. Finally, BlackRock Inc. grew its position in Adamis Pharmaceuticals by 203.2% in the 3rd quarter. BlackRock Inc. now owns 889,440 shares of the specialty pharmaceutical company’s stock valued at $3,113,000 after purchasing an additional 596,112 shares during the period. 17.60% of the stock is owned by institutional investors and hedge funds.

ADMP has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Adamis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research note on Friday, January 11th. Maxim Group set a $10.00 price objective on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, March 19th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Adamis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $5.56.

TRADEMARK VIOLATION WARNING: This story was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/15/david-j-marguglio-sells-10579-shares-of-adamis-pharmaceuticals-corp-admp-stock.html.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Read More: Price to Earnings Ratio (PE)

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.